The Zhitong Finance App learned that Johnson & Johnson (JNJ.US) sales in the second quarter exceeded expectations thanks to strong growth in drugs to treat cancer, inflammatory diseases, and intractable depression. According to financial reports, Johnson & Johnson's Q2 revenue reached US$25.31 billion, up 6.6% year over year, exceeding expectations of US$250 million; non-GAAP earnings per share were US$2.90, exceeding expectations of US$0.05.

The Zhitong Finance App learned that Johnson & Johnson (JNJ.US) sales in the second quarter exceeded expectations thanks to strong growth in drugs to treat cancer, inflammatory diseases, and intractable depression. According to financial reports, Johnson & Johnson's Q2 revenue reached US$25.31 billion, up 6.6% year over year, exceeding expectations of US$250 million; non-GAAP earnings per share were US$2.90, exceeding expectations of US$0.05.